A safe and effective dengue virus vaccine needs to stimulate neutralizing antibodies against all four different virus types, or serotypes targeting their unique sites.
Dengue Vaccine - Types, Symptoms, Treatment & Prevention
Several dengue vaccines are under development. Dengvaxia, Sanofi’s live-attenuated tetravalent dengue vaccine is already commercially available in 10 dengue endemic countries.
Several dengue vaccines are under development. Dengvaxia, Sanofi’s live-attenuated tetravalent dengue vaccine is already commercially available in 10 dengue endemic countries.
‘Dengue vaccine can wind up doing more harm than good in children.’
The published study in the Journal of Clinical Investigation discovers that a small subpopulation of antibodies binding to unique sites on each serotype are linked to protection. This information is important for vaccine developers to consider when creating a dengue vaccine. The four dengue virus serotypes are mosquito-borne flaviviruses that infect hundreds of millions of individuals reporting flu like symptoms each year in Southeast Asia, western Pacific Islands and Africa.
During secondary infection The virus can cause severe illness, especially when a person who has previously infected with one serotype and then reinfected by a second serotype.
Dengue Vaccine can Cause Severe Infection in Some Individuals
Questions have been raised about the continued use of the dengue vaccine due to increased risk of severe infection in persons previously unexposed to the virus.
Questions have been raised about the continued use of the dengue vaccine due to increased risk of severe infection in persons previously unexposed to the virus.
The same phenomenon occurs when dengue vaccine induced antibody response weighted towards a single dengue virus serotype.
Advertisement
New Dengue Related Biological Markers Discovered
New findings in biomarker panel improve the triage process for patients with dengue and help clinicians determine those who may be at risk of developing moderate to severe disease.
New findings in biomarker panel improve the triage process for patients with dengue and help clinicians determine those who may be at risk of developing moderate to severe disease.
Though the vaccine stimulated neutralizing antibodies that recognized epitopes common among all serotypes, it did not protect children from dengue.
Advertisement
Link Between Dengue and COVID-19
People who had dengue in the past are twice as likely to develop COVID-19 symptoms.
People who had dengue in the past are twice as likely to develop COVID-19 symptoms.
Source-Medindia
